Medtronic pacing lead
This article was originally published in The Gray Sheet
Executive Summary
Firm launches the SelectSecure pacing lead in the U.S. after receiving premarket approval Aug. 3. SelectSecure is the "world's thinnest bipolar lead" and the first allowing selective lead placement in the right atrium or right ventricle, away from the apex of the ventricle, according to the firm. Medtronic says that right-side leads have traditionally been affixed near the apex because it was the easiest site to access, but that new research suggests this may cause the two chambers of the heart to beat disjointedly, potentially leading to atrial fibrillation...
You may also be interested in...
Chart: FDA August 2005 Report of Medical Device Approvals
FDA August 2005 Report of Medical Device Approvals
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.